DEVELOPING AND ASSESSING AN IMMUNOCHROMATOGRAPHIC STRIP FOR DETECTING OSTEOARTHRITIS BASED ON URINE CARTILAGE OLIGOMERIC MATRIX PROTEINS

2014 ◽  
Vol 26 (06) ◽  
pp. 1450072 ◽  
Author(s):  
Yu-Hsien Kao ◽  
Kun-Lieh Wu ◽  
Yuan-Kun Tu ◽  
Shwu Jen Chang ◽  
Chin Chang Yang ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Gold Nanoparticle ◽  
Matrix Protein ◽  
Cell Clone ◽  
Preliminary Test ◽  
Test Strip ◽  
Test Results ◽  
Immunochromatographic Strip ◽  
Western Blot Assay ◽  
Detection Range

An immunochromatographic strip was developed using a gold nanoparticle-conjugated monoclonal antibody to detect cartilage oligomeric matrix protein (COMP) in human urine. The monoclonal antibody anti-hCOMP produced from the hybridoma cell clone, hCOMP, is specific to osteoarthritis (OA), and polycolonal antibodies against COMP proteins were conjugated using a gold nanoparticle (approximately 40 nm) to enable detection. The preliminary test results of the proposed biomarker-prepared strip showed a positive correlation with those obtained using Western-blot assay to urinal COMP and exhibited a reliable detection range from 50 to 400 ng. The visual detection limit of the prepared test strip was 50 ng. The test results of OA patients showed consistent diagnostic agreement compared with clinical X-ray radiography. Thus, based on the detection of COMP from urine, the proposed immunoassay method is suitable for screening and noninvasively diagnosing OA.

Simultaneous detection of phenacetin and its metabolite using a gold nanoparticle-based immunochromatographic test strip

The Analyst ◽  
2021 ◽  
Author(s):  
Jingjing Yao ◽  
Xin-Xin Xu ◽  
Liqiang Liu ◽  
Hua Kuang ◽  
Zhengyou Wang ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Gold Nanoparticle ◽  
Simultaneous Detection ◽  
Test Strip ◽  
Immunochromatographic Test ◽  
Immunochromatographic Strip

We have developed a sensitive and rapid gold nanoparticle-based immunochromatographic strip (GNP-ICS) for the detection of phenacetin (PNCT) using an anti-PNCT monoclonal antibody (mAb). The specific anti- PNCT mAb (2D6)...

Development of a monoclonal antibody for the detection of xylazine in milk and its use in an immunochromatographic strip

2021 ◽  
Author(s):  
Mengjia Chao ◽  
Liqiang Liu ◽  
Aihong Wu ◽  
Shanshan Song ◽  
Xinxin Xu ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Gold Nanoparticle ◽  
Limit Of Detection ◽  
Lateral Flow ◽  
Immunochromatographic Strip ◽  
Naked Eye ◽  
Milk Samples ◽  
Flow Test ◽  
Lateral Flow Test

A gold nanoparticle-based lateral-flow test (GNT) strip was developed to detect xylazine (XYL) in milk. And the limit of detection (LOD) and cut-off value of the GNT assay were evaluated to be 20 and 200 ng mL−1 in milk samples by the naked eye.

Development of a monoclonal antibody-based immunochromatographic strip for the rapid detection of tigecycline in human serum

2021 ◽  
Author(s):  
Chuanlai Xu ◽  
qianqian lu ◽  
Xin-Xin Xu ◽  
Shanshan Song ◽  
aihong wu ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Human Serum ◽  
Rapid Detection ◽  
Immunochromatographic Assay ◽  
Immunochromatographic Strip

In this study, a gold labelled immunochromatographic assay was developed to detect tigecycline (TGC) in human serum. For this purpose, an anti-TGC monoclonal antibody, 2G7, was produced and characterized, and...

Human Monoclonal Antibody Against a gag-Coded Protein of Human Immunodeficiency Virus Produced by a Stable EBV-Transformed Cell Clone

1989 ◽  
Vol 5 (1) ◽  
pp. 73-78 ◽  
Author(s):  
ALBERTO AMADORI ◽  
VINCENZO CIMINALE ◽  
MARIA LUISA CALABRO ◽  
LINO TESSAROLLO ◽  
ERMENEGILDO FRANCAVILLA ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Human Immunodeficiency Virus ◽  
Cell Clone ◽  
Human Monoclonal Antibody ◽  
Transformed Cell ◽  
Immunodeficiency Virus

Current Treatment Approaches to Newly Diagnosed Multiple Myeloma

2021 ◽  
Vol 44 (12) ◽  
pp. 690-699
Author(s):  
Susanne Ghandili ◽  
Katja C. Weisel ◽  
Carsten Bokemeyer ◽  
Lisa Beatrice Leypoldt
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibody ◽  
Plasma Cell ◽  
Cell Clone ◽  
Unmet Need ◽  
Continuous Treatment ◽  
High Dose ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

<b><i>Background:</i></b> Multiple myeloma is a so far incurable malignant plasma cell disorder. During the past 2 decades, treatment paradigms substantially changed when novel drugs were introduced initially in treatment of relapsed disease and subsequently also in first-line treatment. <b><i>Summary:</i></b> Up to now, first-line treatment differs between patients initially classified as transplant eligible and those who are considered as nontransplant eligible. Transplant-eligible patients receive a primary proteasome inhibitor (PI)-based induction which is being combined with an immunomodulating agent and a CD38-directed monoclonal antibody followed by high-dose melphalan therapy and autologous stem cell transplantation with subsequent maintenance treatment with lenalidomide. Patients who are considered as nontransplant eligible receive upfront treatment preferentially with a continuous combination treatment either with a CD38-directed monoclonal antibody in combination with the immunomodulating agent lenalidomide or a lenalidomide-PI combination followed by lenalidomide maintenance. <b><i>Key Messages:</i></b> Primary goal of the initiated treatment is to induce a rapid and deep remission which ideally leads to an eradication of the residual plasma cell clone in sense of a minimal residual disease negativity. Achievement of long-term remission with limited toxicity despite continuous treatment strategies and maintenance or improvement of life-quality is key. Despite successful treatment options, specific difficult-to-treat subgroups, especially patients with high-risk myeloma remain with inferior prognosis and a clear unmet need for novel therapeutic strategies. Future concepts will evaluate cellular treatments and other innovative immunotherapies in first-line treatment in curative intention.

Sign in / Sign up

Export Citation Format

Share Document